Economic evaluation of vaccination: Capturing the full benefits, with an application to human papillomavirus

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL. 5, 2012, Pages 70-76

  Barnighausen T ^a,b   Bloom, D E ^a   Cafiero, E T ^a   O'Brien, J C ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Benefit cost analysis; Economic evaluation; Economics; Externalities; Human papillomavirus vaccine; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PNEUMOCOCCUS VACCINE; WART VIRUS VACCINE;

ANUS CANCER; CONDYLOMA ACUMINATUM; COST BENEFIT ANALYSIS; ECONOMIC EVALUATION; HEALTH; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INVESTMENT; LIFE EXPECTANCY; MOUTH CANCER; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VULVA CANCER; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 84867400501     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03977.x     Document Type: Review

References (64)

1. Henderson RH. World Health Organization Expanded Programme on immunization: progress and evaluation report. Ann N Y Acad Sci 1989; 569: 45-68.
2. Keja K, Chan C, Hayden G, Henderson RH. Expanded programme on immunization. World Health Stat Q 1988; 41: 59-63.
3. Halsey N, Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12weeks of age. Bull World Health Organ 1985; 63: 1151-1169.
4. Light DW. Pricing pharmaceuticals in USA. In: Temple NJ, Thompson A, eds, Excessive medical spending: facing the challenge. Oxford: Radcliffe Publishing, 2006; 63-99.
5. Masia N. The cost of developing a new drug. Washington, DC: US Department of State, 2006.
6. Buckland BC. The process development challenge for a new vaccine. Nat Med [Commentary] 2005; 11: S16-S9.
7. Goveia MG, Ciarlet M, Owen KE, Ranucci CS. Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine. Ann NY Acad Sci 2011; 1222: 14-18.
8. U.S. Food and Drug Administration. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Silver Spring, MD: U.S. FDA, 2006. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108666.htm (last accessed 11 November 2011).
9. CDC. Pertussis. Epidemiology and prevention of vaccine-preventable diseases, 12th edn. Atlanta: CDC, 2010.
10. Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011; 29: 371-386.
11. Lieu T, Meltzer MI, Messonnier ML. Guidance for health economics studies presented to the Advisory Committee on Immunization Practices (ACIP). Atlanta: Centers for Disease Control and Prevention, 2007.
12. Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics 2006; 24: 1133-1142.
13. GAVI Alliance. GAVI's mission. Geneva: GAVI Alliance, 2012 Available from: http://www.gavialliance.org/about/mission/ (last accessed 14 January 2012).
14. GAVI Alliance. Available from: http://www.gavialliance.org (Updated 11 June 2011)
15. Mitchell V, Walker D, Zuber P, Lydon P, Ahun M. Evidenced-based decision making about Hib vaccination. Lancet 2005; 365: 936-937.
16. Bärnighausen T, Bloom DE, Canning D et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine. Vaccine 2011; 29: 2371-2380.
17. Bärnighausen T, Bloom DE, Canning D, O'Brien J. Accounting for the full benefits of childhood vaccination in South Africa. S Afr Med J 2008; 98: 842, 4-6.
18. Bloom DE, Canning D, Sevilla J. The effect of health on economic growth: a production function approach. World Dev 2004; 32: 1-13.
19. Fogel RW. New findings on secular trends in nutrition and mortality: some implications for population theory. In: Rosenzweig MR, Stark O, eds, Handbook of population and family economics. Amsterdam: Elsevier, 1997; 433-481.
20. Edward M, Michael K. Worms: identifying impacts on education and health in the presence of treatment externalities. Econometrica 2004; 72: 159-217.
21. Bobonis GJ, Miguel E, Sharma CP. Iron deficiency anemia and school participation, Poverty Action Lab Paper No 7 Cambridge, MA: Abdul Latif Jameel Poverty Action Lab (J-PAL), 2004.
22. Nokes C, Grantham-McGregor SM, Sawyer AW, Cooper ES, Robinson BA, Bundy DA. Moderate to heavy infections of Trichuris trichiura affect cognitive function in Jamaican school children. Parasitology 1992;104 (Pt 3): 539-547.
23. Bloom DE, Williamson JG. Demographic transitions and economic miracles in emerging Asia. World Bank Econ Rev 1997; 12: 419-455.
24. Alsan M, Bloom DE, Canning D. The effect of population health on foreign direct investment inflows to low- and middle-income countries. World Dev 2006; 34: 613-630.
25. WHO. Haemophilus influenzae type B (Hib). 2005; Available from: http://www.who.int/mediacentre/factsheets/fs294/en/.
26. Bloom DE, Canning D, Seiguer E. The effects of vaccination on cognitive development in the Phillippines. Appl Econ 2012; 44: 2777-2783.
27. Canning D, Razzaque A, Driessen J, Walker DG, Streatfield PK, Yunus M. The effect of maternal tetanus immunization on children's schooling attainment in Matlab, Bangladesh: follow-up of a randomized trial. Soc Sci Med 2011; 72: 1429-1436.
28. Dewey KG, Begum K. Long-term consequences of stunting in early life. Matern Child Nutr 2011; 7 (Suppl 3): 5-18.
29. Ben-Porath Y. Fertility response to child mortality: micro data from Israel. J Polit Econ 1976; 84: 163-178.
30. Trussell J, Olsen R. Evaluation of the Olsen technique for estimating the fertility response to child mortality. Demography 1983; 20: 391-405.
31. Schultz TP. Demand for children in low income countries. In: Rosenzweig MR, Stark O, eds, Handbook of population and family economics. Elsevier Science: Amsterdam, New York, 1997; 349-430.
32. Bloom D, Canning D, Fink G, Finlay J. Fertility, female labor force participation, and the demographic dividend. J Econ Growth 2009; 14: 79-101.
33. Bloom DE, Canning D. Global demographic change: dimensions and economic significance. Popul Dev Rev 2008; 34: 17-51.
34. Prettner K, Bloom DE, Strulik H. Declining fertility and economic well-being: do education and health ride to the rescue? Labour Econ 2012; doi: 10.1016/j.labeco.2012.07.001.
35. John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 2000; 16: 601-606.
36. Roberts RR, Mensah EK, Weinstein RA. A guide to interpreting economic studies in infectious diseases. Clin Microbiol Infect 2010; 16: 1713-1720.
37. WHO. Cervical cancer, human papillomavirus (HPV), and HPV vaccines: key points for policy-makers and health professionals. Geneva: WHO, 2007.
38. Driessen J, Razzaque A, Walker D, Canning D. The effect of childhood measles vaccination on school enrolment in Matlab, Bangladesh. PGDA Working Paper No 81. Cambridge: Programme on the Global Demography of Aging, 2011.
39. Bloom DE, Canning D, Weston M. The value of vaccination. World Econ 2005; 6: 15-39.
40. Bloom DE, Canning D, Seiguer E. The effect of vaccination on cognitive development in the Philippines. Mimeo. 2007
41. Psacharopoulos G, Patrinos HA. Returns to investment in education: a further update. Educ Econ 2004; 12: 113-134.
42. World Bank. Learning for All: investing in people's knowledge and skills to promote development. Washington, DC: World Bank, 2011.
43. WHO. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals. Geneva: WHO, 2007.
44. U.S. Food and Drug Administration. FDA approves expanded uses for Gardasil to include preventing certain vulvar and vaginal cancers. Silver Springs, MD: U.S. FDA, 2008. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/2008/ucm116945.htm (last accessed 11 November 2011).
45. U.S. Food and Drug Administration. Gardasil approved to prevent anal cancer. Silver Springs, MD: U.S. FDA, 2010. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237941.htm (last accessed 11 November 2011).
46. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044.
47. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24 (Suppl 3): S3/11-25.
48. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries - key challenges and issues. N Engl J Med 2007; 356: 1908-1910.
49. Ekwueme DU, Chesson HW, Zhang KB, Balamurugan A. Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003. Cancer 2008; 113 (10 Suppl): 2936-2945.
50. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
51. International Labor Organization. LABORSTA Statistics Database. Geneva: International Labor Organization, 2011.
52. Arrossi S, Matos E, Zengarini N, Roth B, Sankaranayananan R, Parkin M. The socio-economic impact of cervical cancer on patients and their families in Argentina, and its influence on radiotherapy compliance. Results from a cross-sectional study. Gynecol Oncol 2007; 105: 335-340.
53. Marlow LAV, Forster AS, Wardle J, Waller J. Mothers' and adolescents' beliefs about risk compensation following HPV vaccination. J Adolesc Health 2009; 44: 446-451.
54. Brewer NT, Cuite CL, Herrington JE, Weinstein ND. Risk compensation and vaccination: can getting vaccinated cause people to engage in risky behaviors? Ann Behav Med 2007; 34: 95-99.
55. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007; 97: 1322-1328.
56. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41.
57. Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med 2011; 53 (Suppl 1): S29-S35.
58. Canfell K, Shi JF, Lew JB et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 2011; 29: 2487-2494.
59. Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac J Cancer Prev 2008; 9: 459-466.
60. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010; 46 (4 Suppl): S20-S26.
61. Vanagas G, Padaiga Z, Kurtinaitis J, Logminiene Z. Cost-effectiveness of 12- and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania. Scand J Public Health 2010; 38: 639-647.
62. Goldie SJ, Kim JJ, Kobus K et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007; 25: 6257-6270.
63. Diaz M, Kim JJ, Albero G et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008; 99: 230-238.
64. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007; 26: 128-139.